Data files

Proteomic Quantification of the Metabolic Targets in Tumor vs Adjacent Normal Liver Tissues

Consistently Altered Metabolic Targets in Human Hepatocellular Carcinoma

APAP

Supplmentary Materials, Methods, Figures and Tables

List of used antibodies

Publications in which periportal fibrosis has been reported after repeated doses of CCl4.

Materials and Methods

PBC scoring of liver fibrosis in 12 to 84 weeks old Abcb4ko mice. Correlation analysis is based on Test z versus 12-weeks-old mice (PPTX 69 KB)

Abcb4ko mouse age, gender and number. Experiment 1 was used to investigate chronic liver disease development and progression. Experiment 2 was performed to test the anti-fibrotic efficiency of Galunisertib. (PPTX 36 KB)

Negative controls for IHC as used in this study. In the same staining batch, negative controls by omitting first antibodies were included. Scale bars are 100 µm. (PPTX 5991 KB)

Body and liver weight as well as liver enzymes upon Galunisertib treatment in 26-weeks-old Abcb4ko mice. a–c mouse and liver weight, and liver as percentage of total body weight. No significant difference is present due to Galunisertib administration. d–f) liver enzymes in Galunisertib, vehicle and untreated mice. e) H&E staining across different groups. Scale bars are 200 µm. Data are means ± SD of 5–7 mice per group. N.S.: P > 0.05; *: P < 0.05; **: P < 0.01 compared with untreated ...